Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the pharmacodynamic profile (antiaggregant profile, balance of prostanoids and nitric oxid) of a ASA-SR (slow-release)formulation in comparison with a ASA NR (normal release), 150 mg, during 12 months of treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rottapharm Spain
• Treatments: Aspirin; Salicylates; Salicylic Acid

Criteria

Inclusion Criteria:

• Previous episodes of myocardial infarction

• Previous episodes of instable angina pectoris

• Previous coronary revascularization

• Significant arterial coronary disease

Exclusion Criteria:

• Patients with other pathologies that require treatment with other antiaggregants

• Patients in treatment with low molecular weight heparin or oral anticoagulants

• Patients with antecedents of hypersensibility to ASA